Physician profile
Sanjay Varma
NPI 1760593487
$8,196.32
in general payments reported to CMS, 2019-2025
36 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.90 · 2020: $539 · 2021: $1,085 · 2022: $2,602 · 2023: $1,199 · 2024: $1,581 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,503.62 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,342.46 | 2020-2025 | Caplyta |
| Lundbeck LLC | $720.37 | 2020-2025 | Rexulti |
| Axsome Therapeutics, INC. | $545.25 | 2023-2025 | Auvelity |
| Abbvie INC. | $478.43 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $431.92 | 2019-2022 | |
| Tris Pharma INC | $358.11 | 2023-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $332.03 | 2020-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $321.62 | 2020-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $319.22 | 2020-2025 | Rexulti |
| Lilly USA, LLC | $289.71 | 2022-2024 | Amyvid, Kisunla |
| Corium, LLC | $284.28 | 2022-2025 | Azstarys, Adlarity |
| Janssen Pharmaceuticals, INC | $260.11 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $252.65 | 2019-2023 | Austedo, Austedo Xr |
| Allergan, INC. | $138.92 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $109.87 | 2020-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $82.67 | 2020-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $72.19 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $48.61 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $39.42 | 2024 | |
| Genentech USA, INC. | $38.18 | 2025 | Gazyva |
| Indivior INC. | $37.82 | 2020-2021 | |
| Biogen, INC. | $33.11 | 2021 | |
| Alkermes, INC. | $29.91 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.74 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2025 | Cobenfy |
| Eisai INC. | $17.00 | 2023 | |
| Neos Therapeutics, LP | $16.12 | 2024 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $14.77 | 2021 | |
| Almatica Pharma LLC | $14.00 | 2025 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $12.91 | 2021 | |
| Noven Therapeutics, LLC | $11.93 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.